Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
about
Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonComparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.Pharmacotherapy for childhood obesity: present and future prospects.Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitusCardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Incretin-based therapies: focus on effects beyond glycemic control alone.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.
P2860
Q27027877-6C5CAEE8-C829-440E-9BBE-A55CE203AE02Q28071764-7B60DABC-C6D1-4AE6-95B8-C7AFBE931E7DQ28238585-786EC271-C45B-4432-AD1A-CE81B307CD6CQ33785197-8AF6E413-47DB-4312-B985-EDACD4794966Q35964678-EE52ECFF-3ADE-4F62-83C6-ED517142BC20Q36468087-B1B3FAD1-B535-4384-BB47-A5D7C5094C97Q36523423-3AC391FD-72EB-4D2B-9E91-55BAC2F51495Q36649277-F823F2D8-7852-41C8-AF5C-1BDB96702222Q37164446-B4E923E5-1631-4901-8336-7E9EB4297798Q37509313-54496D7A-4DFF-4747-8597-D71AA4EC223BQ38004088-720D5F7A-2224-4D37-80AB-B7781BE10086Q38046641-D09D7C6B-E60F-4282-B440-6754A3C24E18Q38106411-0F874210-C928-4E52-9955-C982D0F471B3Q38140803-0ED296C1-2DA0-4086-9D09-324034737BF5Q38177173-3D5A3583-EA50-4702-AD1F-CE2BF0D71834Q38527885-7D9756FD-678C-49B9-8750-E5EDADBA1FD0Q38762377-35C87689-C20B-43EA-91F3-710864B47A55Q38845574-14EC1EF6-7F6D-4435-B687-67AA3856E0F1Q40492085-0A7822AA-C351-4671-86C1-0C23593FA1B4Q41966262-2BDEFD3F-9025-4697-B63E-796CC91E417CQ42633492-FFD44C1D-FF23-4254-8651-3FBA590947DEQ44548336-9B4E0C31-B570-4755-82C4-B400694191D8Q46624867-3BA82182-38E5-4431-A028-50FC33281267
P2860
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@en
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@nl
type
label
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@en
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@nl
prefLabel
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@en
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@nl
P2093
P2860
P921
P1476
Efficacy and safety of sitagli ...... patients with type 2 diabetes.
@en
P2093
A Pérez-Monteverde
B J Goldstein
D E Williams-Herman
K D Kaufman
P2860
P304
P356
10.1111/J.1742-1241.2011.02749.X
P577
2011-09-01T00:00:00Z